A Phase 2, Open-label, Single-arm, Intra-subject Dose-escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2017
At a glance
- Drugs Ponesimod (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 05 Apr 2017 Status changed from active, no longer recruiting to discontinued.
- 09 Dec 2016 Planned End Date changed from 1 Jul 2017 to 1 Jun 2017.
- 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.